Brain folds offer new biomarker for antipsychotic drugs

Developing new antipsychotic medications has proven to be a tough challenge in the biopharma world, in part because of an absence of effective biomarkers. A new study, though, concludes that the complex folds seen on the surface of the brain could provide a solid clue to how a patient suffering from ailments like schizophrenia or bipolar disorder may respond to a therapy, offering a new avenue for personalizing therapies as well as recruiting better patient populations for clinical studies. Report

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.